目的 观察芪骨胶囊联合注射用重组特立帕肽治疗骨质疏松症的临床疗效。方法 选取2020年1月—2021年3月南阳医学高等专科学校第一附属医院收治的111例骨质疏松症患者，根据治疗方案的不同将所有患者分为对照组（54例）和治疗组（57例）。对照组患者大腿或腹部皮下注射注射用重组特立帕肽，20μg/次，1次/d。治疗组患者在对照组的基础上口服芪骨胶囊，3粒/次，3次/d。28d为1个疗程，共治疗6个疗程。观察两组的临床疗效，比较两组的不同部位骨密度、骨吸收和骨形成指标。结果 治疗后，治疗组的总有效率为94.74%，高于对照组患者的总有效率77.78%，组间比较差异显著（P<0.05）。治疗后，两组腰椎L_2～4、股骨颈、桡骨远端1/3处的骨密度均较治疗前升高（P<0.05），且治疗后治疗组的腰椎L_2～4、股骨颈、桡骨远端1/3处的骨密度高于对照组（P<0.05）。治疗后，两组血清Ⅰ型原胶原C-端前肽（PICP）、骨特异性碱性磷酸酶（BALP）、骨钙素（BGP）水平均较治疗前升高（P<0.05），且治疗后，治疗组的血清PICP、BALP、BGP水平高于对照组（P<0.05）。治疗后，两组血清抗酒石酸酸性磷酸酶（TRACP）、Ⅰ型胶原C-末端肽交联（S-CTX）水平均较治疗前下降（P<0.05），且治疗后治疗组的血清TRACP、S-CTX水平低于对照组（P<0.05）。结论 芪骨胶囊联合注射用重组特立帕肽治疗骨质疏松症具有较好的临床疗效，可有效改善机体骨密度，调节血清PICP、BALP、BGP、TRACP、S-CTX水平。

ObjectiveTo observe the clinical therapeutic effect of Qigu Capsules combined with Recombinant Teriparatide for injection in treatment of osteoporosis. MethodsPatients (111 cases) with osteoporosis in the First Affiliated Hospital of Nanyang Medical College from January 2020 to March 2021 were divided into the control group (54 cases) and the treatment group (57 cases) according to different treatment plans. Patients in the control group were sc administered with Recombinant Teriparatide for injection in thigh or abdomen, 20 μg/time, once daily. Patients in the treatment group were po administered with Qigu Capsules on the basis of the control group, 3 grains/time, three times daily. A course of treatment had 28 d, and patients in two groups were treated for 6 courses. After treatment, the clinical efficacies were evaluated, and the bone density in different parts, bone resorption and bone formation markers in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.74%, which was higher than that (77.78%,) of the control group, with a significant difference between two groups (P < 0.05). After treatment, the bone mineral density of lumbar vertebra L_{2— 4}, femoral neck, and distal 1/3 of radius in two groups were increased compared with those before treatment (P < 0.05), and after treatment, the bone mineral density of lumbar vertebra L_{2— 4}, femoral neck, and distal 1/3 of radius in treatment group was higher than that in the control group (P < 0.05). After treatment, the serum levels of PICP, BALP, and BGP in two groups were higher than those before treatment (P < 0.05), and after treatment, the serum levels of PICP, BALP, and BGP in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of TRACP and S-CTX in two groups were decreased compared with those before treatment (P < 0.05). And after treatment, the serum levels of TRACP and S-CTX in the treatment group were lower than those in the control group (P < 0.05). Conclusion Qigu Capsules combined with Recombinant Teriparatide for injection has clinical curative effect in treatment of osteoporosis, can effectively improve the body’s bone mineral density and regulate the serum levels of PICP, BALP, BGP, TRACP, and S-CTX.

R982

河南省科技计划项目（182102310466）